RxDoctor Payments Data

Mandel Miller, MD

Family Medicine · Orlando, FLNPI 1740370048

Payments from drug & device makers

$2,278in general payments, 2019–2025

Across 110 payments — averaging $20.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$752
  • Pfizer$296
  • AstraZeneca$213
  • AbbVie$197
  • Exact Sciences$166
  • Boehringer Ingelheim$161
  • plus $493 from 15 others

What the payments were for

  • Food & beverage$2,16295%
  • Education$1165%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,278 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$81,973
Medicare patients
236
Services billed
856

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate48$61,510
JardianceEmpagliflozin51$59,058
EliquisApixaban57$54,076
FarxigaDapagliflozin Propanediol22$38,779
RybelsusSemaglutide22$33,502
TradjentaLinagliptin36$31,046
JanumetSitagliptin Phos/Metformin Hcl20$22,025
OzempicSemaglutide15$14,249
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$9,533
Advair HfaFluticasone Propion/Salmeterol21$8,958
Fluticasone-SalmeterolFluticasone Propion/Salmeterol28$6,627
Breo ElliptaFluticasone/Vilanterol15$6,000
Atorvastatin Calcium589$5,706
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,462
SymbicortBudesonide/Formoterol Fumarate14$4,572

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$161$90,10487 claims
PfizerEliquis$296$54,07657 claims
Novo NordiskRybelsus, Ozempic$752$47,75137 claims
AstraZenecaFarxiga, Symbicort$213$43,35136 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$54$20,99440 claims
AbbVieSynthroid$197$3,61578 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →